CEP 37251

Drug Profile

CEP 37251

Alternative Names: ART 010; CEP-37251; EGX-010; OPG analogue; OPG variant; OPG variant protein; Osteoprotegerin analogue; Osteoprotegerin variant; Osteoprotegerin variant protein; OVP - Arana Therapeutics

Latest Information Update: 19 Feb 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator EvoGenix
  • Developer Teva Pharmaceutical Industries
  • Class Antineoplastics; Osteoporosis therapies
  • Mechanism of Action RANK ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bone cancer
  • Discontinued Osteoporosis

Most Recent Events

  • 08 Jul 2010 Phase-I clinical trials in Osteoporosis in Australia (Parenteral)
  • 16 Feb 2010 Preclinical development is ongoing in USA
  • 10 Aug 2009 Arana Therapeutics has been acquired by Cephalon
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top